Rosiglitazone Effect on Mitochondria and Lipoatrophy

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to examine the effect of rosiglitazone on limb fat and mitochondrial indices in HIV-1-infected subjects receiving stable antiretroviral therapy that does not contain stavudine (d4T) or zidovudine (AZT).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
• Collaborator: GlaxoSmithKline
• Treatments: Rosiglitazone

Criteria

Inclusion Criteria:

• Lipoatrophy

• Thymidine sparing ARV for at least 24 weeks

• Prior thymidine NRTIs for at least 12 months

Exclusion Criteria:

• Diabetes

• Heart failure

• Liver disease

• Hormonal therapies